The US Food and Drug Administration (FDA) has granted 510(k) approval to Vital Images' CT transcatheter aortic valve replacement (TAVR) planning application.
TAVR procedures, in general, use endovascular techniques to replace faulty aortic valves with artificial valves in patients who cannot withstand invasive surgeries, claims the company.
CT TAVR planning application has been designed for use in the planning process to visualize and measure vascular anatomy for the evaluation, treatment and follow up of aortic vascular disorders.
Vital Images marketing and business development vice president Justin Noznesky said, "Vital is pleased to offer new tools like our CT TAVR planning application that can help our customers provide meaningful information to make clinical decisions."
Vital Images, a Toshiba Medical Systems Group company, said it will display its application at the American College of Cardiology (ACC) annual scientific session, which will be held at San Francisco, California, US from 9-11 March 2013.
